- Investing Ideas
- /
- Mexican Pharmaceuticals & Biotech Potentially Undervalued Companies
Mexican Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Dec 06, 2023
Companies with a Value score of at least 3, ordered by Value score
52 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BMY *Bristol-Myers Squibb | US$868.88 | 1.4% | -45.0% | US$101.5b | US$1,117.16 | PE12.3x | E11.4% | 4.6% | ||
| ARDX *Ardelyx | US$87.95 | 37.3% | n/a | US$1.2b | US$165.00 | PS8.9x | E72.3% | n/a | ||
| BAYN NBayer | €595.00 | -22.0% | -46.2% | €31.8b | €923.74 | PB1x | E66.0% | 7.4% | ||
| ATOS *Atossa Therapeutics | US$12.85 | 0.4% | -4.8% | US$92.1m | US$83.04 | PB0.9x | E73.6% | n/a | ||
| AMGN *Amgen | US$4,549.05 | 0% | -17.1% | US$144.2b | US$4,662.35 | PE19.1x | E5.7% | 3.2% | ||
| NSTG *NanoString Technologies | US$29.32 | 0% | -78.8% | US$28.3m | US$250.26 | PE-0.2x | E36.0% | n/a | ||
| BCRX *BioCryst Pharmaceuticals | US$113.92 | 0% | -57.8% | US$1.1b | US$320.75 | PS3.3x | E73.2% | n/a | ||
| SOBI NSwedish Orphan Biovitrum | kr567.34 | 0% | 0% | kr64.7b | kr746.39 | PE20.4x | E15.6% | n/a | ||
| GSK NGSK | UK£629.00 | -0.2% | n/a | UK£58.7b | UK£754.48 | PE9.7x | E6.1% | 3.9% | ||
| ROG NRoche Holding | CHF5,020.91 | 6.5% | -22.6% | CHF201.3b | CHF6,197.04 | PE18.1x | E10.9% | 3.8% | ||
| SAN1 NSanofi | €1,629.20 | 0% | -11.7% | €108.0b | €1,993.70 | PE11.9x | E7.0% | 4.1% | ||
| SNY NSanofi | €813.92 | 1.7% | -7.0% | €108.0b | €996.02 | PE11.9x | E7.0% | 4.1% | ||
| AGIO *Agios Pharmaceuticals | US$432.08 | 0% | -33.7% | US$1.4b | US$612.41 | PS75.6x | E13.7% | n/a | ||
| ENDPQ NEndo International | US$169.00 | 0% | n/a | US$19.2m | US$2,068.54 | PE-0.006x | n/a | n/a | ||
| ZLAB NZai Lab | US$443.30 | 0% | -26.6% | US$2.8b | US$1,113.87 | PS10.6x | E54.4% | n/a | ||
| MRK1 NMerck KGaA | €3,358.91 | 0% | -8.8% | €69.7b | €4,326.25 | PE21x | E8.7% | 1.4% | ||
| AZN1 NAstraZeneca | UK£2,196.58 | 0% | -5.5% | UK£157.2b | UK£2,851.88 | PE33.5x | E19.4% | 2.2% | ||
| 1093 NCSPC Pharmaceutical Group | HK$15.69 | 0% | -27.0% | HK$81.2b | HK$22.49 | PE11.7x | E2.6% | 4.2% | ||
| BGNE NBeiGene | US$3,860.00 | 0% | -41.9% | US$18.8b | US$6,676.29 | PS12.1x | E60.9% | n/a | ||
| PHM1 NPharma Mar | €1,608.38 | 0% | 0% | €601.5m | €2,866.23 | PE20.9x | E26.7% | 2.0% | ||
| NVS NNovartis | CHF1,754.60 | 0% | n/a | CHF174.5b | CHF1,913.26 | PE24.5x | E10.2% | 3.5% | ||
| 4528 NOno Pharmaceutical | JPÂ¥341.69 | 0% | -34.5% | JPÂ¥1.3t | JPÂ¥362.67 | PE9.9x | E-5.0% | 3.1% | ||
| HCM NHUTCHMED (China) | UK£819.63 | 0% | 0% | UK£1.6b | UK£1,868.97 | PS4.7x | E53.8% | n/a | ||
| ABCM NAbcam | US$292.38 | 0% | -2.5% | US$3.7b | US$360.48 | PS8.1x | E37.2% | 0% |